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Abstract: Toxin-antitoxin (TA) systems are found in nearly all prokaryotic genomes and usually
consist of a pair of co-transcribed genes, one of which encodes a stable toxin and the other, its cognate
labile antitoxin. Certain environmental and physiological cues trigger the degradation of the antitoxin,
causing activation of the toxin, leading either to the death or stasis of the host cell. TA systems have a
variety of functions in the bacterial cell, including acting as mediators of programmed cell death, the
induction of a dormant state known as persistence and the stable maintenance of plasmids and other
mobile genetic elements. Some bacterial TA systems are functional when expressed in eukaryotic
cells and this has led to several innovative applications, which are the subject of this review. Here,
we look at how bacterial TA systems have been utilized for the genetic manipulation of yeasts and
other eukaryotes, for the containment of genetically modified organisms, and for the engineering of
high expression eukaryotic cell lines. We also examine how TA systems have been adopted as an
important tool in developmental biology research for the ablation of specific cells and the potential
for utility of TA systems in antiviral and anticancer gene therapies.
Keywords: toxin-antitoxin systems; genetic manipulation; gene containment; cell ablation;
high expression cell lines; gene therapy; antiviral therapy; anticancer therapy
1. Introduction: An Overview of Bacterial Toxin-Antitoxin Systems
Toxin-antitoxin (TA) systems are nearly ubiquitous genetic modules in bacterial and archaeal
genomes. They generally comprise a pair of genes coding for a stable toxin and its cognate labile
antitoxin. Under normal growth conditions, the toxin is prevented from exerting its lethal effect by the
antitoxin. However, environmental stresses usually cause a drastic drop in the levels of the unstable
antitoxin in the cell due mainly to degradation by endogenous proteases. This leads to activation of
the remaining toxin which, in turn, causes either cell death or cell stasis [1–5].
TA systems were initially discovered encoded within bacterial plasmids where they function to
mediate plasmid maintenance and stability through the postsegregational killing of any plasmid-free
daughter cells that arise within a population. The bacterial hosts became “addicted” to the presence of
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these TA-encoding plasmids and thus, TA systems were also termed as addiction modules [6,7].
Chromosomal homologues of these plasmid-encoded addiction modules were first reported in
Escherichia coli and the chromosomal mazEF system, comprising the mazE-encoded antitoxin and
the mazF-encoded toxin, was postulated to mediate programmed bacterial cell death under nutrient
starvation conditions [8]. This apparent altruistic killing was envisaged to enable part of the bacterial
population to survive during adverse conditions, reflecting a multicellular facet of bacteria [8–10].
Research into other chromosomal TA systems in E. coli, namely the relBE system and chpAIK
(a mazEF homologue), appeared to indicate an alternative role. Overexpression of the relE- and
chpAK-encoded toxins in E. coli induces a bacteriostatic condition with severe inhibition of translation,
but subsequent induction of expression of the respective cognate antitoxins relB and chpAI fully reverses
the toxin-induced stasis [11,12]. relBE and other similar TA systems were proposed to function as part
of the general stress response of bacteria by regulating the global level of translation and together with
the trans-translation ssrA system, function in the quality control of gene expression [1,13]. However,
with increasing numbers of novel TA systems being discovered, their biological functions have
expanded, mirroring their genetic diversity. TA systems have been implicated in various other cellular
processes such as the formation of persister cells leading to antibiotic tolerance [14,15], as anti-addiction
modules [16], in protection against invading bacteriophages [17,18], as stabilization modules for large
mobile genetic elements such as superintegrons and genomic islands [19,20], in biofilm formation [21]
and in virulence of pathogenic bacteria [22–24].
TA systems have so far been broadly classified into five different types, designated types I–V, based
on the characteristics of the antitoxin and the mechanisms by which they counteract the toxins [4,5,19].
In type I TA systems, the antitoxin is an antisense RNA that binds to the toxin mRNA, preventing its
translation [25]. In type II TA systems, both antitoxin and toxin are proteins and the antitoxin functions
by direct binding with the toxin, usually blocking its active site [2]. As for type III TA systems, the
antitoxin is an RNA that functions by direct binding, with the toxin protein leading to the formation of
a non-lethal protein-RNA complex [26]. In type IV systems, both antitoxins and toxins are proteins but
unlike in type II systems, the antitoxins and toxins of type IV systems do not directly interact with
each other. Rather, the antitoxin binds to the target of the toxin to prevent the toxin from exerting its
lethal effect [27]. Finally, in type V systems, the antitoxin is a protein with ribonuclease activity that
cleaves the toxin mRNA and thus prevents the synthesis of the toxin [28]. Nevertheless, a potentially
new class of TA system (a possible type VI) was recently discovered in the form of the SocAB system
from Caulobacter crescentus [29]. Both the SocB toxin and the SocA antitoxin are proteins but in this case,
the SocB toxin is the unstable partner due to its susceptibility to the endogenous ClpXP protease. The
SocA antitoxin functions as an essential ClpXP adaptor for the SocB toxin, promoting its degradation
and thus abolishing its lethality [30]. To date, TA systems belonging to types I and II are the most
abundant in prokaryotes with type II TAs being the most well-characterized [5,19].
TA toxins target a wide variety of essential cellular structures and processes such as membrane
integrity, cell wall synthesis, DNA replication, ribosome assembly and translation factors, with
RNA cleavage being the most prevalent mode of action [3,23]. The near ubiquity of TA systems
in prokaryotes and the potential for triggering latent intracellular molecular timebombs, especially
in pathogenic bacteria, led to several interesting avenues of research for the use of TA systems as
targets for novel antibacterial compounds [5,19,31]. TA systems have also been harnessed as tools
in molecular biology, such as for the positive selection of clones containing inserted DNA fragments
in cloning vectors. The ccdB toxin gene of the ccdAB TA system from the E. coli F plasmid has been
successfully used in a number of cloning vectors where the toxin gene is inactivated upon insertion of
foreign DNA, enabling only insert-containing clones to survive and grow [19,32]. With the discovery
that some of these bacterial TA systems can be expressed and are functional in eukaryotic cells [33–35],
several interesting applications have been proposed and developed. In this mini-review, we will look
at several strategies used for the heterologous expression of bacterial TA genes in eukaryotic systems
and their potential applications in biotechnology and molecular biology.
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2. Expression of TA Systems in Yeasts: Applications
2.1. TA Systems as Tools for Containment in Yeasts
The increasing use of genetically modified organisms (GMOs) in various bioprocesses necessitates
appropriate containment strategies to address concerns over the accidental release of these GMOs into
the environment, or in cases where the deliberate release of the GMOs into the environment are required
for biotechnological applications (such as bioremediation, bioleaching and biopesticides) [36,37].
Two main strategies that have been utilized are passive and active containment systems [36]. In passive
containment systems, the GMO is engineered such that it cannot synthesize an essential compound;
thus, when these auxotrophic GMOs accidentally escape from the bioreactor or environment where
the compound is provided, the organisms will likely die. Recently, “genetically-recoded” bacteria have
been engineered whereby the expression of several essential genes is totally reliant on the supply of
exogenously supplied synthetic amino acids, resulting in the death of these cells in an environment
lacking these synthetic compounds [38,39]. However, such synthetic auxotrophy systems require
extensive genome-wide engineering and hence, may not be technologically and economically practical
for eukaryotic systems at this point in time. In active containment systems, the GMO is engineered
with a controllable lethal function that will not interfere with normal cellular processes until a specific
environmental cue is triggered. TA systems have been utilized as the controllable lethal function in
several such active containment strategies for bacteria and these have been recently reviewed [36,40].
The E. coli relBE TA system was demonstrated to be functional in the yeast Saccharomyces cerevisiae
and was proposed as a containment system for genetically modified yeast [33]. The pYES2 yeast
expression vector was used for this purpose with two recombinant plasmids constructed: pKP727 with
the relE toxin gene under the control of the GAL1 promoter; and pKP1006 with relE controlled by the
GAL1 promoter and the relB antitoxin gene under the control of the MET25 promoter [33]. Expression
of relE in yeast cells transformed with pKP727 and induced with galactose showed clear inhibitory
effects, whereas in yeast cells that were transformed with pKP1006 and induced with galactose in
the absence of methionine (for the co-expression of both relE and relB), higher growth rates were
observed, albeit lower than normal [33]. This indicated that the RelE toxin is lethal in S. cerevisiae and
its toxicity could be somewhat neutralized by co-expression of the RelB antitoxin. However, since
that research was published in 2000 [33], there have not been any follow-up reports on the utility of
relBE or any other TA system for the containment of genetically modified yeasts. A general strategy
that could be used to engineer such a TA-based containment system is depicted in Figure 1. Other
TA systems have been shown to be functional in S. cerevisiae and this includes the kis-kid TA system
from the E. coli plasmid R1 [35] and ε-ζ from plasmid pSM19035 of Streptococcus pyogenes [41]. The
kis-kid genes were expressed in S. cerevisiae using a similar system to relBE in that the kis antitoxin was
expressed from a MET25 promoter (i.e., induced expression in the presence of methionine), whereas
the kid toxin was under the control of the CUP1 promoter (induced expression in the presence of Cu2+)
in an integrative pRS303-derived plasmid recombinant [35]. The ε-ζ genes were, however, expressed
by vectors designed for a commercial yeast two-hybrid system (Matchmaker Two-Hybrid System kit
from Clontech). Toxicity of the ζ toxin in S. cerevisiae was demonstrated, as was its neutralization by
its cognate ε antitoxin and interaction between the toxin and antitoxin proteins [41]. The RelE and
Kid toxins are endoribonucleases [13,42] whereas the ζ toxin functions by blocking bacterial cell wall
synthesis by phosphorylating uridine diphosphate-N-acetylglucosamine (UNAG), a key intermediate
in peptidoglycan synthesis [43]. In S. cerevisiae, the nucA gene from the Gram-negative bacteria Serratia
marcescens has been successfully used to construct a conditional lethal system for containment by
placing the nucA gene under the control of the glucose-repressed S. cerevisiae alcohol dehydrogenase-2
ADH2 gene promoter [44]. It was proposed that the small size of the S. marcescens nuclease (26 kDa)
facilitates its entry into the yeast nucleus [44] and it is likely to be the same situation for the smaller
~12 kDa RelE and Kid endoribonuclease toxins. The lethal mechanism for the ζ toxin in yeast is still
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unknown although it could act to inhibit the synthesis of the yeast cell wall much like in bacteria, as
UNAG is a component for the biosynthesis of chitin in yeast [45].
Toxins 2016, 8, 49  4 of 16 
 
of the yeast cell wall much like in bacteria, as UNAG is a component for the biosynthesis of chitin in 
yeast [45]. 
Two new microbial “kill switches” were recently engineered based on the CcdB and MazF TA 
toxins (along with the EcoRI restriction endonuclease) for the containment of genetically modified 
bacteria.  These  switches,  designated  “Deadman”  and  “Passcode”  are  modular  and  flexible 
(customizable), can be conveniently transferred to other bacterial strains [46] and would therefore be 
useful in vari s biotherapeu ic and  ndustrial applications. The e toxin‐based sw tches should also 
be functional in yeasts and could likewis  be adopted for the containment of genetically modified yeasts. 
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toxin‐coding gene (red arrow) are cloned under the control of two separate promoters (depicted as 
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nutrients such as glucose and specific amino acids), the antitoxin is expressed whereas expression of 
the toxin gene is repressed (indicated by orange “+” and “−“ signs, respectively). Any leaky expression 
of the toxin gene (depicted as a dotted arrow) would be countered by the continual expression of the 
antitoxin. However, in the absence of the specific signal, such as when the genetically modified yeast 
has escaped into the environment, transcription of the antitoxin gene will be repressed whereas the 
toxin gene will be actively transcribed, thus killing the escaped organism. 
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Expression of another endoribonuclease toxin, MazF, from the tightly controlled, methanol‐inducible 
AOX1 promoter in the methylotrophic yeast Pichia pastoris, was found to be lethal. This was used as 
the  basis  of  a  novel method  for  unmarked  genetic modification  of  P.  pastoris  using mazF  as  a   
counter‐selectable marker  [47]. A modular plasmid, pKSCTMF, was  constructed  consisting of an 
AOX1  promoter‐mazF  expression  cassette  and  a  Zeocin‐resistance  gene  as  a  dominant  selection 
marker  flanked  by direct  repeats  from  segments  of  the CYC1  transcriptional  terminator  (TT),  as 
recombination  sites,  along  with  multiple  restriction  sites  to  permit  subcloning  of  fragments 
homologous  to  the P. pastoris genome  for disruption  [47]. P. pastoris was  first  transformed with a 
linearized  recombinant pKSCTMF construct and selected on medium supplemented with Zeocin. 
Transformants with  the  correct disruption were determined  by phenotype  and/or PCR  analysis. 
Subsequently, selection for recombination of the two CYC1 TT repeats was performed by growing 
Figure 1. General strategy utilizing a bacterial TA system to engineer a containment system for
genetically modified yeasts. The antitoxin-coding gene (depicted by a green arrow) and the toxin-coding
gene (red arrow) are cloned under the control of two separate promoters (depicted as yellow and
blue triangles) within the same yeast vector. Under controlled conditions (such as in a fermenter),
the presence of a specific signal (which can either be a certain media constituent or nutrients such as
glucose and specific amino acids), the antitoxin is expressed whereas expression of the toxin gene is
repressed (indicated by orange “+” and “´“ signs, respectively). Any leaky expression of the toxin
gene (depicted as a dotted arrow) would be countered by the continual expression of the antitoxin.
However, in the absence of the specific signal, such as when the genetically modified yeast has escaped
into the environment, transcription of the antitoxin gene will be repressed whereas the toxin gene will
be actively transcribed, thus killing the escaped organism.
Two new microbial “kill switches” were recently engineered based on the CcdB and MazF
TA toxins (along wit the EcoRI restricti n endonuclease) for the containment of genetically
modified bacteria. T se switches, design ted “De dman” and “Passcode” ar modular and flexible
(custom zable), can be conveniently transferred to other bacteri l strains [46] nd would therefore be
useful in various biotherapeutic and industrial applications. These toxin-based switches should also be
functional in yeasts nd could likewise be adopted for the containment of genetically modified yeasts.
2.2. TA Systems as Tools for the Genetic Manipulation of Yeasts
Expres ion of another endoribonuclease toxin, MazF, from the tightly controlled,
methanol-inducible AOX1 promoter in the methylotrophic yeast Pichia astoris, was found to
be lethal. This was used as the basis of a novel method for u marked genetic modification of P. p storis
using mazF as a counter-selectable m rker [47]. A modular plasmid, pKSCTMF, was constructed
consisting of an AOX1 promoter-mazF expression cassette and a Zeocin-resistance gene as a dominant
selection marker flanked by direct repeats from segments of the CYC1 transcriptional terminator
(TT), as recombination sites, along with multiple restriction sites to permit subcloning of fragments
homologous to the P. pastoris genome for disruption [47]. P. pastoris was first transformed with a
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linearized recombinant pKSCTMF construct and selected on medium supplemented with Zeocin.
Transformants with the correct disruption were determined by phenotype and/or PCR analysis.
Subsequently, selection for recombination of the two CYC1 TT repeats was performed by growing
the transformants on methanol medium plates that would enable only transformants with a single
CYC1 TT segment inserted into the disrupted site to survive [47], i.e., effectively disrupting the gene of
interest and subsequently evicting the selectable markers. This would enable the disrupted strains
to be amenable for a second or multiple genetic modifications using the same MazF-ZeoR cassette
(marker recycling). This method also enabled knock-in of a gene of interest as well as site-directed
mutagenesis at the native locus [47].
A variant of this method was utilized to enable disruption of certain genes that were less amenable
to gene replacement in P. pastoris such as OCH1 that encodes α-1,6-mannosyltransferase and for
which gene replacement occurs at frequencies of <1% even with flanking arms that are longer than
1 kb [48]. Here, the AOX1 promoter-mazF cassette was cloned into an episomal “helper” plasmid that
also contained a full copy of the OCH1 gene, providing a functional backup of the OCH1 gene for
P. pastoris before deletion to avoid compromising the fitness of the yeast cells due to possible loss of
function. P. pastoris carrying this helper plasmid was then used as the host for conventional OCH1 gene
disruption using a Zeocin-resistance gene [48]. Once replacement of the chromosomal OCH1 gene
with the Zeocin-disrupted copy had been validated, these strains were grown in medium containing
methanol to induce expression of mazF. This exerts a strong selection pressure for the strains to lose
the episomal “helper” plasmid. The same strategy was used to successfully delete the KU70 and SGS1
genes in P. pastoris, and increasing their targeting efficiencies [48].
3. TA Systems as Cell Ablation Tools
3.1. Cell Ablation for the Containment of Genetically Modified Plants
Transgenic crops have become integrated into modern agriculture and are increasingly adopted
worldwide. Besides having useful traits such as herbicide resistance and pest tolerance, transgenic
plants have also served as a platform for the large-scale production of recombinant pharmaceutical
proteins (also known as biopharming) and industrial enzymes [49]. One of the major concerns of the
wide-scale adoption of transgenic crops is their accidental spread into the environment leading to
contamination of the human food chain. This concern is not without precedent as several episodes of
accidental release or contamination have occurred, leading to a negative perception of GM crops in the
eyes of the public [49,50]. In addition to physical containment methods, biological containment
strategies such as plastid transformation, male sterility and genetic use restriction technologies
(GURTs) have been proposed or developed to confine the potential spread of transgenic crops [51–53].
Engineered sterility of transgenic plants is not only helpful in preventing their pollen spread into
natural ecosystems, it is also useful for the development of male sterile parents for hybrid seed
production [54] in self-pollinated crops, for the removal of allergenic pollen and for the production of
seedless varieties of fruit and vegetable crops [55]. To achieve sterility, a toxin gene is placed under the
control of a tissue-specific promoter that enables the toxin to be expressed in certain parts of the plant
anther and/or pistil.
One of the earliest and successfully applied bacterial toxin genes that has been used for the specific
ablation of the plant’s reproductive organs leading to sexual sterility is Barnase, a small 12.4-kDa RNase
of 110 amino acid residues produced by Bacillus amyloliquefaciens that also synthesizes its antidote, a
small protein called Barstar (89 amino acid residues) that binds to Barnase and sterically blocks the
Barnase active site in a one-to-one noncovalent interaction [56]. Barnase has been used since the 1990’s
to engineer male, female or bisexual sterility in various transgenic plants by placing the barnase gene
under the control of a tissue-specific promoter, which enables it to be expressed in certain parts of the
plant anther and/or pistil [56–61]. Expression of barnase leads to the destruction of the reproductive
organs, thereby conferring sterility to the transgenic plants. Although not a TA system, Barnase-Barstar
Toxins 2016, 8, 49 6 of 16
is illustrative of the utility of a bacterial regulatory module where the toxic effect can be rescued by the
specific counterpart; in the case of sexually sterile (barnase expressing) plants, this has been applied
by the expression of barstar in “fertility restorer” plant lines, when viable pollen or seed is required
for hybrid seed production [62]. Unlike in TA systems, the genes for Barnase and Barstar are not in
an operon and are located in different loci in the B. amyloliquefaciens genome, suggestive of distinct
regulation of their expression [56]. However, this is not a barrier to similar application of TA systems,
since the toxin and antitoxin can be expressed as independent units in a transgenic context and in fact
this permits differing expression levels, for example, stronger expression of the “restorer” molecule
when required [62]. Other bacterial or bacteriophage toxins or enzymes that have been applied for
negative selection in plants include the expression of the restriction endonuclease EcoRI in tobacco
pollen [63] and cytosine deaminase from E. coli and the dipththeria A-chain toxin (DT-A) subunit from
corynephages of Corynebacterium diptheriae for gene targeting in rice [64].
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Figure 2. Schematic diagram  illustrating  the Gateway‐compatible two‐component  inducible expression 
system used by Abu Bakar et al. [65] for the expression of the YoeBSpn toxin from Streptococcus pneumoniae 
in the model plant Arabidopsis thaliana. The genetic organization of the T‐DNA regions flanked by the 
left border  (LB) and  right border  (RB) of  the  recombinant activator vector, pMDC150_35S and  the 
recombinant responder vector, pMDC221_yoeB‐GFP, are shown. The cauliflower mosaic virus (CaMV) 
35S promoter was cloned in between the Gateway attR recombination sites (indicated in dark blue 
boxes) of  the pMDC150 activator vector enabling  the  constitutive expression of  the XVE chimeric 
transcriptional activator in transgenic plants. The yoeBSpn toxin gene was cloned as a translational fusion 
with the green fluorescent protein gene, GFP in between the attR recombination sites of the responder 
vector pMDC221,  thus placing  the yoeB‐GFP  fusion gene under  the control of  the XVE‐responsive 
promoter  (OlexA‐TATA). Both pMDC150_35S  and pMDC221_yoeB‐GFP were  co‐transformed  into   
A.  thaliana  via Agrobacterium  tumefaciens‐mediated  transformation  [65].  Transcription  of  yoeB‐GFP  in 
transgenic A. thaliana only occurs in the presence of the inducer 17‐β‐estradiol that activates the XVE 
activator. The vectors also contain the nos promoter (nosP) to drive the expression of the kanamycin 
resistance gene (KanR) in pMDC150 and the hygromycin resistance gene (hpt) in pMDC221 for plant 
selection. The pMDC221 T‐DNA also contains the pBluescript vector sequence (pBSK; grey rectangle), 
which can be used for plasmid rescue procedures due to the presence of the ampicillin resistance gene 
and the ColE1 origin of replication, which enables replication in E. coli [66]. TE9, TE9 terminator; T3A, 
terminator; nosT, nos terminator. 
The variety of toxin targets for bacterial TA toxins gives researchers a choice of toxins to use for 
specific  cell  ablation.  Like  Barnase‐Barstar,  each  of  these  TA  toxins  are  available  with  their 
corresponding  antitoxins, which  can  be  used  to modulate  the  expression  of  the  toxin  to  avoid 
excessive  levels  of  the  toxin,  which  may  spread  to  other  tissues  causing  undesirable  effects. 
Transgenic  Brassica  napus  plants with  barnase  being  ectopically  expressed  from  a  seed myrosin   
cell‐specific Myr1.Bn1 promoter were  found  to be embryo  lethal. Co‐expression of  barstar  from a 
constitutive cauliflower mosaic virus (CaMV) 35S promoter enabled selective and controlled death 
of myrosin cells without affecting plant viability [67]. Until now, only the YoeBSpn endoribonuclease 
Figure 2. Schematic diagram illustrating the Gateway-compatible two-component inducible expression
system used by Abu Bakar et al. [65] for the expression of the YoeBSpn toxin from Streptococcus
pneumoniae in the model plant Arabidopsis thaliana. The genetic organization of the T-DNA regions
flanked by the left border (LB) and right border (RB) of the recombinant activator vector, pMDC150_35S
and the recombinant responder vector, pMDC221_yoeB-GFP, are shown. The cauliflower mosaic
virus (CaMV) 35S promoter was cloned in between the Gateway attR recombination sites (indicated
in dark blue boxes) of the pMDC150 activator vector enabling the constitutive expression of the
XVE chimeric transcriptional activator in transgenic plants. The yoeBSpn toxin gene was cloned as a
translational fusion with the green fluorescent protein gene, GFP in between the attR recombination
sites of the responder vector pMDC221, thus placing the yoeB-GFP fusion gene under the control
of the XVE-responsive promoter (OlexA-TATA). Both pMDC150_35S and pMDC221_yoeB-GFP
were co-transformed into A. thaliana via Agrobacterium tumefaciens-mediated transformation [65].
Transcription of yoeB-GFP in transgenic A. thaliana only occurs in the presence of the inducer
17-β-estradiol that activates the XVE activator. The vectors also contain the nos promoter (nosP) to drive
the expression of the kanamycin resistance gene (KanR) in pMDC150 and the hygromycin resistance
gene (hpt) in pMDC221 for plant selection. The pMDC221 T-DNA also contains the pBluescript vector
sequence (pBSK; grey rectangle), which can be used for plasmid rescue procedures due to the presence
of the ampicillin resistance gene and the ColE1 origin of replication, which enables replication in
E. coli [66]. TE9, TE9 terminator; T3A, terminator; nosT, nos terminator.
The variety of toxin targets for bacterial TA toxins gives researchers a choice of toxins to use
for specific cell ablation. Like Barnase-Barstar, each of these TA toxins are available with their
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corresponding antitoxins, which can be used to modulate the expression of the toxin to avoid
excessive levels of the toxin, which may spread to other tissues causing undesirable effects. Transgenic
Brassica napus plants with barnase being ectopically expressed from a seed myrosin cell-specific
Myr1.Bn1 promoter were found to be embryo lethal. Co-expression of barstar from a constitutive
cauliflower mosaic virus (CaMV) 35S promoter enabled selective and controlled death of myrosin cells
without affecting plant viability [67]. Until now, only the YoeBSpn endoribonuclease toxin from the
YefM-YoeBSpn TA system of the Gram-positive human pathogen Streptococcus pneumoniae [68] has been
demonstrated to be functionally lethal in the model plant Arabidopsis thaliana [65] and our unpublished
results indicated that co-expression of the cognate YefMSpn antitoxin was able to abrogate the lethality
of YoeBSpn in A. thaliana. A two-component XVE-based inducible expression system was used to assess
the functionality of the YoeBSpn toxin in A. thaliana (Figure 2) [65]. XVE is a chimeric transcription
activator comprising of the DNA-binding domain of the LexA bacterial repressor, the transactivating
domain of VP16 and the C-terminal region of the human estrogen receptor ER and is strictly activated
by estradiol in transgenic plants [69]. The yoeBSpn transgene was cloned as a translational fusion
with the green fluorescent protein (GFP) gene under the control of the XVE-responsive promoter
(consisting of the LexA operator sequence fused to a 35S minimal promoter) [65,66]. Activation occurs
when the inducer 17-β-estradiol binds to the XVE activator, enabling it to bind to the LexA operator
sequences and thereby activating transcription of the cloned transgene. Plant defects and tissue
necrosis were observed in 17-β-estradiol-induced transgenic A. thaliana expressing the YoeBSpn-GFP
fusion 3 days after induction followed by plant death over a period of 9 days [65]. The system is
tightly regulated with no detectable transactivating activity in the absence of an inducer [66,69]. Hence,
despite containing a cytotoxic gene such as the dipththeria A-chain toxin (DT-A) [66] and YoeBSpn [65],
transgenic plants developed normally in the absence of the inducer. At this juncture, the use of
YoeBSpn or any other bacterial TA toxins for the ablation of specific plant cells has yet to be carried out.
Nevertheless, the potential is there and we are currently exploring the possibility of developing male
sterile plants by using tissue-specific promoters to express the yoeBSpn toxin gene.
3.2. Cell Ablation in Developmental Biology Research of Higher Eukaryotes
The E. coli plasmid R1-encoded kis-kid TA system was shown to be functional in yeast [35].
To investigate its functionality in higher eukaryotes, purified TA proteins were microinjected into
embryos of the frog Xenopus laevis as well as the human cell lines HeLa and SW480 [35]. Injection of
the Kid toxin into two-cell embryos of X. laevis led to failure of the Kid-injected blastomere to develop
normally, unlike blastomeres that were injected with a combination of Kid and its antitoxin Kis.
The Kid-injected half embryo showed very few cells, most of which were anucleated [35]. The effect
was equally lethal in human cell lines, as microinjection of Kid into HeLa and SW480 cells drastically
decreased their survival and eventually led to their death. The lethality of Kid was completely
abrogated when Kis was preincubated with Kid prior to microinjection [35]. Ablation of a specific
cell type in a developing organism using the Kis-Kid TA system was subsequently successfully
demonstrated for zebrafish (Danio rerio) in targeting primordial germ cells [70]. One-cell-stage embryos
were injected with mRNA encoding for kid fused to the 31-UTR of the zebrafish nos1 gene, which
directs expression of the Kid toxin preferentially to the primordial germ cells. The treatment effectively
eliminated the primordial germ cells and resulted in somatic defects and embryonic death due likely
to leaky expression of kid in other cells [70]. To protect the somatic cells from the lethal effects of
kid expression, the mRNA of the kis antitoxin gene fused to the globin 31-UTR was co-injected along
with the kid-nos1-31-UTR mRNA. These embryos showed primordial germ cell loss but appeared
morphologically normal and could be raised to adulthood without any somatic defects. Interestingly,
all the germ cell-ablated embryos developed as sterile male adult fish that were capable of inducing
females to lay eggs but not in fertilizing the eggs due to undeveloped gonads. It was thus concluded
that in zebrafish, the germ line is essential for the development of females but is dispensable for
the development of male somatic tissues with the exception of the gonad [70]. The findings also
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demonstrated that TA proteins could be applied for highly specific ablation of targeted eukaryotic
cells, hence a potentially important tool in developmental studies.
The kis-kid genes were also cloned into expression vectors and transfected into human cell lines to
investigate whether independent transcriptional control of the TA genes would enable regulated cell
killing or survival in human cells [35]. In one of the recombinant constructs, the kid toxin gene was
placed under the control of the constitutive cytomegalovirus (CMV) early promoter while transcription
of the kis antitoxin gene was controlled from a tetracycline-repressible promoter in which the presence
of the tetracycline analogue, doxycycline, would lead to transcriptional repression in HeLa TetOff
cells [35]. The kis and kid genes were cloned in a tail-to-tail orientation. When Kid was expressed
without Kis in the transfected HeLa TetOff cell lines (i.e., in the presence of doxycycline), cell death
was widespread beyond three days, with total cell death after 15 days. Such a lethal effect was not
observed in the absence of doxycycline (i.e., co-expression of Kid and Kis), indicating that inhibition
of cell proliferation can be modulated in human cells through independent transcriptional control
of kis and kid [35]. Similar observations were reported earlier for experiments conducted with the
E. coli-encoded RelE toxin in a human osteosarcoma cell line, TREx-U2OS [34]. In this case, the relE
gene was cloned under the control of a Tet promoter-operator and in the TREx-U2OS cells, the Tet
repressor is constitutively expressed. Hence, in the transfected TREx-U2OS cells, expression of relE is
induced by addition of tetracycline. Expression of RelE was indeed detrimental to cell growth with
estimation of less than 1 in 108 cells surviving the expression of the toxin and metabolic activity as
measured using the MTT assay, showing an obvious decline 12 h after tetracycline induction [34].
However, Yamamoto et al. [34] did not show if co-expression of the cognate RelB antitoxin was able to
counteract the toxic effects of RelE expression. The authors did indicate that cells that were induced for
RelE expression showed morphological changes that are characteristic of apoptosis such as membrane
budding, reduction in cell volume, chromatin condensation and fragmentation. DNA laddering,
typical of caspase-activated DNase was also shown [34]. HeLa cells expressing the Kid toxin were also
demonstrated to undergo apoptosis through propidium iodide and Annexin-V staining, which are early
markers of apoptosis, along with the characteristic morphological changes [35]. A more extensive study
was carried out by Shimazu et al. [71], who showed that expression of the E. coli MazF toxin in human
T-Rex-293 cells resulted in cellular mRNA degradation, inhibition of protein synthesis and induction
of apoptosis with activation of the caspase-3 executioner caspase. The pathway that was utilized to
activate apoptosis triggered by MazF-induced mRNA cleavage, was also elucidated resulting in the
identification of the BH3-only proapoptotic protein NBK/BIK as a mediator of apoptosis induced by
adenovirus infection [71].
4. TA Systems as Tools for Overproduction of Heterologous Proteins in Eukaryotic Cells
The strength and stability of transgene expression in transfected mammalian cell lines depends
mainly on the chromosomal integration site, which occurs mostly at random. A lot of time and
effort is required to screen and identify stable transfected clones that highly overexpress the gene of
interest [72]. Nehlsen et al. [73] developed a method that utilized the Kis-Kid TA system to enable a
more efficient selection and enrichment of mammalian cells that highly express recombinant genes.
The initial step in this strategy is to stably establish in transfected CHO-K1 cells the ability for controlled
expression of the kid toxin gene, which was placed under Tet-dependent transactivation control. Cells
were cultivated in the presence of doxycycline (Dox) to protect the cells from the lethality of Kid.
Cell clones were evaluated for viability of growth in the presence and absence of Dox with clones
selected that showed normal growth in the presence of Dox and at least 80% cell death when grown
without Dox for 10 days [73]. These cells were then transfected with a plasmid from which the gene of
interest and the kis antitoxin gene were transcriptionally coupled using an internal ribosome entry
site (IRES) that enabled a bicistronic arrangement in eukaryotic cells. Expression data from three
different transgenes (luciferase, eGFP and an IgG antibody, the genes of which were driven by an SV40
promoter), showed that transfectants that expressed the Kid toxin steadily increased their transgene
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expression over several weeks (up to 100-fold increase for the IgG antibody), whereas in the absence of
toxin expression, transgene expression in the transfectants dropped over the same period of time [73].
The increased expression within the pools of kid-transfected cells was possibly due to a selection
process for highly expressing clones created by random integration of the transgene-kis cassette. Cells
with reduced expression levels are likely eliminated or are over-grown. Thus, to apply this system in
other cells, the lethal effect of kid or any other TA toxin expression needs to be validated in the cell
line of interest. Furthermore, coupled expression of the gene of interest with the kis or other antitoxin
genes must be achieved [73].
5. TA Systems in Gene Therapy
5.1. Antiviral Gene Therapy
The development of TA systems for application in antiviral gene therapy is seemingly feasible, as
has been demonstrated in several elegant studies, and strategies to employ them as possible drugs
were thoroughly described previously [31]. As most of the toxins of TA systems are ribonucleases,
this would have potential in particular for the control of RNA viruses. To exploit TA systems as
antivirals, specificity has become a major concern, as while bacterial endoribonuclease toxins usually
cleave at specific RNA sequences or sites, they are not cell-specific. Activation of toxin effect through a
viral promoter in response to its specific protein, and activation through cleavage by a specific viral
protease, are two rather clever approaches to explicitly tackle the viral-infected cells. The first approach
is exemplified by the Tat (transactivator of transcription) protein, which is a viral regulator protein
produced during the early stage of HIV-1 infection by HIV-1 viruses. The Tat protein is essential
in HIV infection as HIV-1 mutants lacking a functional tat gene are not able to proliferate. The Tat
regulator protein will bind to the specific long terminal repeat (LTR), termed the transactivation
response (TAR) sequence, that consequently induces the production of various HIV-1 proteins for
infection purposes [74]. Thus, therapy using a construct with a toxin gene placed downstream of a TAR
sequence in a retroviral vector, during the early stage of HIV-1 infection, should result in activation
of expression of the toxin gene upon the binding of the Tat regulator protein to the TAR promoter
sequence. MazF is one of the most well-studied TA system toxins, and the E. coli-encoded MazF
functions as an endoribonuclease that cleaves mRNA specifically at ACA codons [75]. The E. coli mazF
gene itself harbors nine ACA codons, and can be engineered to be void of ACA sequences without
altering the amino acid sequences, to prevent self-cleavage and yet maintain the toxic effect. As the
HIV RNA contains over 240 ACA sequences, it is thus a very good target for MazF. It was shown that
when a human T lymphoid line CEM-SS, that is highly prone to HIV infection, was transduced with an
HIV-1-LTR-regulated MazF recombinant plasmid and then infected with HIV-1 IIIB, the replication of
the virus was thwarted, as HIV-1 IIIB p24 could not be detected in the culture medium [74]. In addition,
the CD4 level was also not affected. Fortunately, although MazF was also able to cleave cellular mRNA,
the levels of induced MazF did not seem to cause serious cell damage and thus normal cellular growth
was maintained. Similar results were also observed in an experiment whereby the Tat-dependent
MazF expression system was performed in rhesus macaque primary CD4+ T cells from monkeys that
were infected with the suppressed chimerical virus simian/human immunodeficiency virus SHIV
89.6P [74].
In general, the shift of a patient from chronic phase to AIDS phase is caused by the continuous
growth of the HIV virus and the body’s suppressed immune system that fails to protect the infected
cells, which subsequently lead to decreases in CD4+ T cells. Therefore, the inhibition of viral growth
by the MazF-based therapy to control and protect the cells from HIV viruses and to maintain the
immune system is somewhat important. To examine the persistence and the in vivo safety of the
MazF-transduced autologous CD4+ T cells (herein called MazF-Tmac cells), cynomolgus macaque
primary CD4+ T cells were first transduced with the HIV-1-LTR-regulated MazF recombinant plasmid,
then infused into the autologous monkeys, and several parameters were monitored for more than half
Toxins 2016, 8, 49 10 of 16
a year [76]. As a result, even though the levels of MazF-Tmac cells in the peripheral blood gradually
decreased, their level was still significantly detected throughout the entire experimental period and
MazF-Tmac cells were also detected in the lymphoid tissues and the spleen. Strikingly, no lesions
were observed and antibodies against MazF were also not detected. Moreover, the gene-modified
cells harvested from the monkeys more than half a year post-infusion were still able to inhibit the
replication of SHIV 89.6P [76]. These combined results reflect the persistency and safety of this
promising MazF-based anti-HIV virus approach.
Besides Tat-dependent activation of the MazF toxin, another interesting approach made use of viral
proteases, which cleave at specific cleavage sites, to activate the toxin to explicitly target the infected
cells. A non-structural serine protease (NS3)-activated MazF system was constructed, in which NS3-4A
is a hepatitis C virus (HCV) protein that is important in the replication of HCV. The NS3-activated
MazF construct was designed by fusing the NS3 protease cleavage site in between MazF and the
truncated C-terminal of MazE, which is the cognate antitoxin of MazF, and thus the resulting products
neutralize the toxic effect of MazF. MazF can be activated by incubating the inert proteins with NS3
protease that cleaves the linker in between the MazE and MazF proteins, thereby releasing the MazF
toxin [77]. The same principle applies to other viral proteases such as HIV-1 protease and factor Xa [77].
When a similar construct of the NS3-activated MazF system, termed “zymoxin”, was placed in HEK293
T-REx cells that harbored the tetracycline-inducible NS3–4A constructs, NS3-mediated activation of
MazF that inhibited cellular protein synthesis was observed. However, unlike the MazF-Tmac cells,
cytotoxic effects were observed although this was with low levels of NS3 [78]. Thus, the dosage of
MazF needs be fine-tuned to eliminate its harmfulness to human cells to make this antiviral approach
more feasible.
5.2. Anticancer Gene Therapy
Although TAs are absent in eukaryotic cells, TA toxins have been found to inhibit growth in
Saccharomyces cerevisiae and Arabidopsis thaliana (see above). More interestingly, these toxins were
able to trigger apoptosis in human cells [34,35]. This finding has opened new avenues to explore
the feasibility of using TAs as tools to develop anti-tumor drugs [79,80]. The hypothesis was based
on the finding that the toxins Kid from plasmid R1 [81], and MazF from the chromosome of E. coli
(reviewed by [82]) were able to induce apoptosis in eukaryotic cells. It was found that induction of
apoptosis by MazF toxin in human cells was dependent of the BAK pro-apoptotic protein and its
upstream regulator NBK/BIK; cells defective in BAK, however, did not exhibit apoptosis but MazF
was still able to cause total inhibition of protein synthesis [71]. Even though not many studies on
the activity of prokaryotic toxins on oncogenic cells have been reported, it has been recently shown
that toxins VapC 22 (from the chromosome of Mycobacterium tuberculosis H37Rv), and PasB (from
plasmid pTF-FC2 from Thiobacillus ferroxidans) exhibit pro-apoptotic activity in diverse human cancer
cell lines [83]. However, most of these studies have been conducted using cell-cultures (i.e., under
in vitro conditions) transfected with plasmids harboring genes encoding the bacterial toxin [84]. Then,
there are a number of remaining questions to be tackled, such as how to target cancer cells with TAs
while avoiding potential harmfulness to the normal cells? Are there activator-regulatory proteins
present in oncogenic cells that could be used to mimic the antiviral therapy mentioned above? And last,
but not least, what ways can be envisaged to deliver the desired anti-cancer toxin into tumor cells and
not into healthy cells?
Stable expression of a foreign gene integrated within the chromosome of a mammalian cell would
depend greatly on a number of factors, but especially on the region where integration occurred, on the
surrounding DNA context (adjacent genes, DNA structure), and on the promoter used to express the
transgene. In many instances, integration occurs randomly if no targeted site has been chosen. This
makes it very tedious and difficult to detect the cells that have integrated the transgene. Consequently,
a targeted integration site would be generally favored. An excellent and imaginative approach to
tackle the above questions and to achieve stable expression of heterologous genes in eukaryotic cells is
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proposed using the Agrobacterium tumefaciens Ti plasmid machinery, or any other T4 secretion system
(T4SS) protein complex, to specifically integrate the desired genetic information within any eukaryotic
chromosome [85]. T4SS is used by bacteria to translocate and transport DNA-protein complexes from
a donor to a recipient cell (Figure 3). This strategy has been used to develop gene cassettes that make
use of the site-specific recombinase and integrase ability of some bacterial plasmid-encoded relaxases
(proteins devoted to conjugative transfer between bacteria or between bacteria and eukaryotes).
In some cases, it has been shown that the target sequence for the relaxase to perform a strand transfer
reaction could be as short as 17 nucleotides, and furthermore, the relaxase can integrate the transferred
DNA into the nucleus of eukaryotic cells if it finds sequences homologous to its target in the recipient
cells [86]. We speculate that the relaxase activity could be also used to efficiently integrate the desired
genes into eukaryotic chromosomes, provided some stretches of homologous DNA are cloned within
the incoming plasmid DNA [86,87]. Employment of these cassettes is predicted to function in an
efficient manner for gene therapy with specific targeting into the recipient chromosome, rather than
random integration [88]. If the incoming plasmid harbors a toxin-encoding gene and some specific
tumor-related DNA region, we could envisage that, at least as a preliminary experimental approach,
integration of the toxin gene into the desired chromosome region of tumor cells would be feasible.
If, in addition, the toxin gene is cloned under the control of any oncogenic-specific promoter, or
any inducible promoter that can be used in eukaryotic cells, then we could also consider that some
targeted-vectors could be used to employ toxins as specific anti-cancer tools.
Toxins 2016, 8, 49  11 of 16 
 
into the recipient chromosome, rather than random integration [88]. If the incoming plasmid harbors 
a toxin‐encoding gene and some specific tumor‐related DNA region, we could envisage that, at least 
as a preliminary experimental approach, integration of the toxin gene into the desired chromosome 
region of tumor cells would be feasible. If, in addition, the toxin gene is cloned under the control of 
any oncogenic‐specific promoter, or any inducible promoter that can be used in eukaryotic cells, then we 
could also consider that some targeted‐vectors could be used to employ toxins as specific anti‐cancer tools. 
 
Figure  3.  Possible  way  to  deliver  an  RNase  toxin  into  the  chromosome  of  a  tumor  cell.   
The plasmid‐encoded relaxase (depicted in pink) harbors a toxin gene (denoted as a red arrow), and 
a DNA stretch homologous to the chromosome of the recipient cell (shown as green lines). The relaxase 
recognizes and initiates transfer from the donor (bacterial) cell by means of the protein‐DNA complex 
formed by the relaxase, auxiliary proteins (green), and oriT (shadowed). This complex is pumped into 
the recipient tumor cell by the coupling protein (CP, shown in orange) and the T4SS export system 
(in  blue).  The  relaxase‐DNA  enters  into  the  nucleus  and  integrates  its  cargo  transgene  into  the 
chromosome of the recipient cell. Induction of the toxin leads to RNA cleavage and tumor cell stasis. 
6. Conclusions 
Our knowledge of bacterial TA systems has improved tremendously over the past two decades 
since their initial discovery in bacterial plasmids and then, bacterial chromosomes, where they were 
postulated  to mediate programmed bacterial cell death  [8]. These small genetic modules are now 
known  to be  almost ubiquitous  in bacterial  and  archeael genomes  and  to play  essential  roles  in 
diverse  cellular  processes  [2,3,89]. As we  have  shown  in  the  above  review,  the  finding  that TA 
systems are functional in eukaryotic cells has opened the door to various innovative biotechnological 
and  biomedical  applications. With  the  inevitable  growth  in  our  fundamental  knowledge  of  TA 
systems  and  with  more  novel  TA  systems  being  discovered,  further  refinements  to  existing 
applications will  be  seen  and  even more  interesting  and  novel  applications will  be  presented.   
TA systems have indeed came a long way since the time when they were viewed as small, curious 
genetic entities that helped to maintain the stability of bacterial plasmids to their present position as 
one of the important tools in the toolbox used in the current on‐going biotechnology revolution. 
Figure 3. Possible way to deliver an RNase toxin into the chromosome of a tumor cell.
The plasmid-encoded relaxase (depicted in pink) harbors a toxin gene (denoted as a red arrow),
and a DNA stretch homologous to the chrom some of the recipient cell (shown as green lines). The
relaxase r cogniz s and initiates transfer from the don (bacterial) cell by means of the protein-DNA
complex formed by the relaxas , a xiliary proteins (green), and oriT (shadowed). This complex is
pumped into the recipient tumor cell by the coupling protein (CP, shown in orange) and the T4SS
export system (in blue). The relaxase-DNA enters into the nucleus and integrates its cargo transgene
into the chromosome of the recipient cell. Induction of the toxin leads to RNA cleavage and tumor
cell stasis.
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6. Conclusions
Our knowledge of bacterial TA systems has improved tremendously over the past two decades
since their initial discovery in bacterial plasmids and then, bacterial chromosomes, where they were
postulated to mediate programmed bacterial cell death [8]. These small genetic modules are now
known to be almost ubiquitous in bacterial and archeael genomes and to play essential roles in diverse
cellular processes [2,3,89]. As we have shown in the above review, the finding that TA systems
are functional in eukaryotic cells has opened the door to various innovative biotechnological and
biomedical applications. With the inevitable growth in our fundamental knowledge of TA systems
and with more novel TA systems being discovered, further refinements to existing applications will be
seen and even more interesting and novel applications will be presented. TA systems have indeed
came a long way since the time when they were viewed as small, curious genetic entities that helped
to maintain the stability of bacterial plasmids to their present position as one of the important tools in
the toolbox used in the current on-going biotechnology revolution.
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